company background image
PAA

PharmAustASX:PAA Stock Report

Market Cap

AU$29.8m

7D

4.4%

1Y

-35.2%

Updated

15 Oct, 2021

Data

Company Financials
PAA fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

PAA Overview

PharmAust Limited, a clinical-stage company, develops targeted cancer therapeutics for humans and animals.

Price History & Performance

Summary of all time highs, changes and price drops for PharmAust
Historical stock prices
Current Share PriceAU$0.094
52 Week HighAU$0.081
52 Week LowAU$0.14
Beta0.73
1 Month Change4.44%
3 Month Change0%
1 Year Change-35.17%
3 Year Change100.00%
5 Year Change14.64%
Change since IPO-98.96%

Recent News & Updates

Oct 14
This Is The Reason Why We Think PharmAust Limited's (ASX:PAA) CEO Might Be Underpaid

This Is The Reason Why We Think PharmAust Limited's (ASX:PAA) CEO Might Be Underpaid

Shareholders will be pleased by the impressive results for PharmAust Limited ( ASX:PAA ) recently and CEO Roger Aston...

Shareholder Returns

PAAAU PharmaceuticalsAU Market
7D4.4%0.03%0.1%
1Y-35.2%-2.5%19.3%

Return vs Industry: PAA underperformed the Australian Pharmaceuticals industry which returned -2.5% over the past year.

Return vs Market: PAA underperformed the Australian Market which returned 19.3% over the past year.

Price Volatility

Is PAA's price volatile compared to industry and market?
PAA volatility
PAA Beta0.73
Industry Beta1.31
Market Beta1

Stable Share Price: PAA is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: PAA's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2000n/aRoger Astonhttps://www.pharmaust.com

PharmAust Limited, a clinical-stage company, develops targeted cancer therapeutics for humans and animals. The company develops drugs for the treatment of various cancers, and viral and neurological diseases. Its lead candidate is Monepantel (MPL), a small molecule drug for the treatment of cancer.

PharmAust Fundamentals Summary

How do PharmAust's earnings and revenue compare to its market cap?
PAA fundamental statistics
Market CapAU$29.79m
Earnings (TTM)-AU$1.34m
Revenue (TTM)AU$3.66m

8.2x

P/S Ratio

-22.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PAA income statement (TTM)
RevenueAU$3.66m
Cost of RevenueAU$225.32k
Gross ProfitAU$3.43m
ExpensesAU$4.77m
Earnings-AU$1.34m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.0042
Gross Margin93.84%
Net Profit Margin-36.57%
Debt/Equity Ratio0.4%

How did PAA perform over the long term?

See historical performance and comparison

Valuation

Is PharmAust undervalued compared to its fair value and its price relative to the market?

3.35x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate PAA's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate PAA's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: PAA is unprofitable, so we can't compare its PE Ratio to the Oceanic Pharmaceuticals industry average.

PE vs Market: PAA is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PAA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PAA's PB Ratio (3.4x) is in line with the AU Pharmaceuticals industry average.


Future Growth

How is PharmAust forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

65.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as PharmAust has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has PharmAust performed over the past 5 years?

18.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PAA is currently unprofitable.

Growing Profit Margin: PAA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PAA is unprofitable, but has reduced losses over the past 5 years at a rate of 18.4% per year.

Accelerating Growth: Unable to compare PAA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PAA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.1%).


Return on Equity

High ROE: PAA has a negative Return on Equity (-15.06%), as it is currently unprofitable.


Financial Health

How is PharmAust's financial position?


Financial Position Analysis

Short Term Liabilities: PAA's short term assets (A$4.4M) exceed its short term liabilities (A$911.4K).

Long Term Liabilities: PAA's short term assets (A$4.4M) exceed its long term liabilities (A$1.2M).


Debt to Equity History and Analysis

Debt Level: PAA's debt to equity ratio (0.4%) is considered satisfactory.

Reducing Debt: PAA had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PAA has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: PAA has sufficient cash runway for 2.3 years if free cash flow continues to grow at historical rates of 14.3% each year.


Dividend

What is PharmAust current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PAA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PAA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PAA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PAA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PAA's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.4yrs

Average management tenure


CEO

Roger Aston (65 yo)

3.42yrs

Tenure

AU$284,700

Compensation

Dr. Roger Aston, B.Sc. (Hons), Ph D., has been Acting Chief Executive Officer of PharmAust Ltd since May 25, 2018. Dr. Aston serves as the Chief Executive Officer at Pitney Pharmaceuticals Pty Ltd.Dr. Ast...


CEO Compensation Analysis

Compensation vs Market: Roger's total compensation ($USD211.12K) is about average for companies of similar size in the Australian market ($USD300.24K).

Compensation vs Earnings: Roger's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: PAA's management team is considered experienced (3.4 years average tenure).


Board Members

Experienced Board: PAA's board of directors are considered experienced (4.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: PAA insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

PharmAust Limited's employee growth, exchange listings and data sources


Key Information

  • Name: PharmAust Limited
  • Ticker: PAA
  • Exchange: ASX
  • Founded: 2000
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$29.790m
  • Shares outstanding: 316.91m
  • Website: https://www.pharmaust.com

Location

  • PharmAust Limited
  • 5/3 Brodie Hall Drive
  • Bentley
  • Western Australia
  • 6102
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/15 15:41
End of Day Share Price2021/10/15 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.